

## Pl Industries Ltd. Investor Presentation

Nov, 2021

Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements," including those relating to general business plans and strategy of PI Industries Limited ("PIIL"), its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. Actual results may differ materially from these forward-looking statements due to a number of factors, including future changes or developments in PIIL's business, its competitive environment, its ability to implement its strategies and initiatives and respond to technological changes and political, economic, regulatory and social conditions in India. This presentation does not constitute a prospectus, offering circular or offering memorandum or an offer, or a solicitation of any offer, to purchase or sell, any shares and should not be considered as a recommendation that any investor should subscribe for or purchase any of PIIL's shares. Neither this presentation nor any other documentation or information (or any part thereof) delivered or supplied under or in relation to the shares shall be deemed to constitute an offer of or an invitation by or on behalf of PIIL.

PIIL, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this presentation, unless otherwise specified is only current as of the date of this presentation. PIIL assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise stated in this document, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. PIIL may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation may not be copied and disseminated in any manner.

THE INFORMATION PRESENTED HERE IS NOT AN OFFER OR SOLICITATION OF ANY OFFER TO PURCHASE OR SELL ANY EQUITY SHARES OR ANY OTHER SECURITY OF PI INDUSTRIES LTD.

#### CDR India

Siddharth Rangnekar <u>siddharth@cdr-india.com</u> Nishid Solanki <u>nishid@cdr-india.com</u>

Tel: +91 22 6645 1221 /1209 Fax: +9122 6645 1213







PI Industries Limited

Rajnish Sarna <u>r.sarna@piind.com</u> Manikantan Viswanathan <u>manikantan@piind.com</u>

> Tel: +91 124 6790000 Fax: +91 124 4081247




## Performance Highlights Q2' FY22

## **Growth continues in Q2'FY22**

YoY Revenue up by 17%, EBITDA by 4%, PAT by 6%

#### CONSOLIDATED






- ✓ **17%** Y-o-Y revenue growth primarily driven by:
  - ~24% growth in Exports contributed by strong volume growth in key products
  - Domestic business growth remained flat on account of global supply chain disruptions impacting imports, adverse weather events in certain herbicide geographies, etc.
- ✓ Gross Margin maintained despite sharp increase in input costs and curtailed export incentives by ~ 1.5%, mainly on account of favourable product mix. Price correction being done to maintain gross margin
- ✓ Overheads increase of **38%** is mainly attributable to sharp increase in fuel and related utilities, one-time expenses pertaining to several strategic initiatives and other Covid19 management costs
- ✓ 4% increase in EBITDA reflects rising input cost.

## H1'FY 22 Performance

YoY Revenue up by 15%, EBITDA by 6%, PAT by 15%

#### CONSOLIDATED





- ✓ **15%** Y-o-Y revenue growth primarily driven by:
  - ~27% growth in Exports contributed by strong volume growth in key products
  - Domestic business impacted due to disruption in global supply chains, adverse weather events impacting herbicide sales in certain geographies, etc
- ✓ Gross Margin improvement reflects increase in input costs, curtailed export incentives by ~ 1.5% and favourable product / business mix.
- ✓ Overheads increase of 33% is mainly attributable to sharp increase in fuel and related utilities, travel cost, one-time expenses pertaining to several strategic initiatives, other Covid19 management costs and reflects in softer EBIDTA improvement.
- ✓ Net profit improved by **15%** YoY with lower ETR

## **Strong liquidity position**

#### showing resilience & growth appetite

|                              |        | •      | 0      |
|------------------------------|--------|--------|--------|
| (Rs in Cr.)                  | Sep-21 | Mar-21 | Sep-20 |
| Shareholders' Funds          | 5,736  | 5,342  | 5,014  |
| Non Current Liabilities      | 359    | 403    | 579    |
| Long-term borrowings         | 214    | 257    | 416    |
| Other long-term liabilities  | 145    | 146    | 163    |
| Current Liabilities          | 1444   | 1257   | 1431   |
| Short – term Borrowings      | 95     | 70     | 46     |
| Trade payables               | 872    | 796    | 913    |
| Other current liabilities    | 477    | 391    | 472    |
| TOTAL                        | 7,539  | 7,002  | 7,024  |
| Non Current Asset            | 2,587  | 2,509  | 2,503  |
| Net Fixed Asset              | 2,414  | 2,343  | 2,149  |
| Good Will                    | 83     | 83     | 83     |
| Non-current investments      | 24     | 21     | 23     |
| Other Assets                 | 66     | 62     | 248    |
| Current Asset                | 4,952  | 4,493  | 4,521  |
| Inventories                  | 1,316  | 1,053  | 990    |
| Trade receivables            | 959    | 852    | 754    |
| Cash, Bank & Investments     | 2,371  | 2,327  | 2393   |
| Other assets                 | 306    | 261    | 384    |
| Total                        | 7,539  | 7,002  | 7,024  |
| Key Ratios (%) (Annualised)  | Sep-21 | Mar-21 | Sep-20 |
| Net Sales to Fixed Assets    | 2.04   | 1.89   | 1.99   |
| Net Sales to Working capital | 3.63   | 4.13   | 5.34   |
| Debt/Equity Ratio            | 0.05   | 0.06   | 0.09   |
|                              |        |        |        |



- ✓ Net sales to Fixed Asses ratio improved to 2.04 (Sep'21) Vs 1.89 (Mar'21)
- ✓ Positive operating Cash flow of Rs. ~208 crore
- ✓ Increased inventory levels maintain to avert supply chain disruptions and meet customer supply schedules / continued operations.
- ✓ Surplus cash net of debt of Rs. ~2,062 crore (including QIP proceeds)
- ✓ QIP funds remains invested into deposits and debt mutual funds with SLR philosophy while final deployment aligned with PI's longer term growth strategy is underway

## **Key Operational Highlights H1'FY22**

#### **Progress on strategic initiatives continues for sustained growth**



|   | Capacity<br>Build-up                    | <ul> <li>Production throughput improved through<br/>process efficiencies releasing 15 production days<br/>accommodated the growth of other products</li> <li>Agreements on non-conventional energy<br/>sourcing executed</li> </ul>            |   | Farm Application<br>Services               | <ul> <li>Additional machines procured</li> <li>Strategic partnership with a manufacturer of international repute exclusively for service</li> <li>Evaluating Drone application trials</li> </ul> |
|---|---|--|---|--|--|
| Ø | New Enquiry/<br>Scale-up                | <ul> <li>3 new products commercialized for exports</li> <li>&gt;40 products at different scale up stages</li> <li>R&amp;D pipeline has &gt;20% non ag-chem products</li> </ul>   |   | Digitalization,<br>Process<br>Improvements | <ul> <li>Rolled out Suppliers Life Cycle Portal of ARIBA</li> <li>Jivagro was integrated with PI Tech Stack and digital tools rolled out.</li> </ul>   |
|   | Customer<br>Acquisition &<br>Order Book | <ul> <li>Initiated manufacturing of electronic chemicals<br/>with global customers</li> <li>Seeing an upsurge in new business enquiries -<br/>&gt;20 enquiries in last 2 quarters</li> <li>Order book remained robust at ~\$ 1.4 Bn</li> </ul> |   | Product<br>Penetration                     | <ul> <li>Rice herbicide (Nominee Gold) dominant share maintained</li> <li>Expanded herbicide share</li> <li>Expansion in horticulture segment with a focused strategy</li> </ul>                 |
|   | Technology<br>Scale-up                  | <ul> <li>Flow chemistry pilot facility operational</li> <li>Bio-chemical process for manufacturing of<br/>pharma intermediates in pilot phase</li> <li>Implemented technology to improve solvent<br/>recovery</li> </ul>                       | $(\mathfrak{Q})$                          | Human Capital<br>and Culture               | <ul> <li>PI new operating model in place - Roll out plan in<br/>the next few quarters</li> <li>Elevation of home grown leaders</li> </ul>  |
|   |   | 0)1/0  | w products launche<br>Dne new Insecticide | ed<br>e for leaf folder in rice            |  |

Market

✓ One new fungicide for Sheath Blight control

## Update on Pharma Acquisition Deal..

#### Background:



- PI signed a business transfer agreement with Ind Swift Laboratory Ltd (ISLL) to acquire their pharma API and Intermediate business on slump sale going concern basis on 30<sup>th</sup> July, 2021.
- The consummation of the transaction and integration into corporate structure of PI was expected to be completed by 31<sup>st</sup> Oct, 2021 being the long stop date subject to fulfilment of pre-agreed closing conditions and regulatory approvals
- As ISLL was not able to complete several of the vital pre-agreed condition precedents before the long stop date and also started renegotiating the pre-agreed terms, the consummation of the deal could not happen before the long stop date and the BTA got terminated.

#### What Next:

- Pls' long term strategy to strengthen presence in custom synthesis exports through diversification into adjacencies including Pharma remains intact.
  - ✓ Advanced technology platforms, digital and backward integration for cost leadership and IP generated by PI continue to hold immense potential
  - Strong underlying momentum in R&D scale ups and investments in established technology partnerships gives added confidence and will provide opportunities to build and scale pharma vision
  - ✓ Continue to vigorously evaluate inorganic options enough opportunities present in the market to provide immediate scale up
- Strong synergy with PI's Core technology Platforms, best-in-class manufacturing competence, and partnerships experience and track record with global innovators will help replicate CSM model in adjacencies.

#### PI's pharma strategy remains unhindered; focused initiatives are on to create differentiated technology play

## **Business outlook remains robust**

#### Targeted expansion backed by solid growth visibility to support momentum Continuous focus on new strategic initiatives to elevate performance



| Domestic:<br>Focus on portfolio diversification with<br>launch of novel offerings | <ul> <li>Positive outlook for owing to late rains and adequate water level at reservoirs</li> <li>2 new products expected to be launched between Q3 and Q4</li> <li>Positive momentum for Awkira adoption and scale up in Wheat herbicide segment</li> <li>Jivagro - Smooth transition to new packaging in ~Q2, improving efficiency &amp; branding</li> </ul>  |
|---|---|
| CSM Export:<br>R&D focused approach to drive<br>incremental business              | <ul> <li>~6 new molecules planned to be commercialized in FY22, out of which 3 molecules are planned in H2.</li> <li>1 MPP has commissioned in Q2 and another MPP is planned for commissioning in Q3</li> <li>Order book continues to remain robust with high visibility of sustainable growth for the next 3 years</li> </ul>  |
| Efforts to drive strategic initiatives continues                                  | <ul> <li>Acquisition of API &amp; Intermediate business undertaking of ISLL called off amid non fulfillment of vital CPs, renegotiation of deal</li> <li>Signed a technology partnerships under joint venture structure in bio-chemical space with a foreign partner. Scale up is expected to start from FY23.</li> <li>Investing in a new R&amp;D facility for deepening our technological capabilities, de-risking current operations and opening up newer opportunities</li> </ul> |
| Pl's product & research efforts<br>yielding promising results                     | <ul> <li>Two promising leads; one novel fungicide and a novel broad spectrum insecticide, having sizable potential market opportunity progressing to development phase</li> <li>One new process innovation is being commercialized</li> <li>Discussions are underway with global innovators for development partnership</li> </ul>  |

#### Maintain original guidance of >15% revenue growth in FY22 and resolutely progressing on that path

## Pl's New Compass



| SP) | Purpose               |  | Reimagining a healthier planet   |
|-----|-----------------------|--|--|
|     | Vision                |  | ology and human ingenuity to address latent nutrition<br>and health needs of the planet  |
| - Č | Spiky<br>Capabilities | Partner CentricScience and Technology drivenDigital EdgePeople FirstESG Anchored | First to identify and deliver on latent needs of our customers and partnersSustainable solutions by early adoption of cutting-edge sciences/technologiesIntegrated digital solutions to gain competitive advantageBest opportunities for employees to learn and growESG a way of life                            |
|     | Values                | Act with integrity and be     accountable     Be o     char                      | CuriousCreativeCreativeCarestion conventional wisdom<br>pen and adaptable to<br>nge<br>elop intellectual curiosity• Differentiate by connecting<br>new dots• Be transparent and bring<br>the best out of people• Collaborate and experiment to<br>bring new thinking forward• Continually innovate processes<br> |

## Preparing PI for its next phase of growth

 Our ambition, in keeping with the times and stakeholder expectations, is to embark on rapid, differentiated, organic and inorganic growth which is resilient by being ahead scientifically and technologically



#### Leadership Announcements

- CSM Exports
  - ✓ Dr. Atul Gupta CEO

#### Domestic Ag Chem Brands

- Prashant Hegde CEO Domestic Agri & Nominee Director, Jivagro
- Jivagro

•

•

- ✓ Parmanand Pandey CEO & Executive Director Jivagro
- Technology Development & Scale up
  - ✓ Dr. P V Srinivas CTO. & Nominee
     Director, PI Fermachem

#### Health Sciences build up

Dr. Saswata Lahiri - Head, Pharma R &D

• With enormous and pervasive technological changes all around, along with the challenges our Planet Earth faces, we recognize we need to make deep changes to make an significant impact

- By Reimaging a Healthier Planet, setting an audacious Vision to address expressed and latent needs of People, by bringing out the genius in our talented and motivated work force, we aim to grow not only rapidly and sustainably
- Implementing a new Operating Model that enables us to continue growing our current businesses, establish new businesses and also continually add new ideas, technologies, scientific discoveries and more to make PI a resilient, resourceful and successful enterprise.
- Empower and enable our home grown leaders and new talent we have acquired to bring out their best whilst ensuring proper and effective accountability. Elevating leaders with demonstrated success to lead Business Units, which make up our Delivery fold while backing them up with the requisite talent, empowering them to succeed.

#### **Restructuring of the Board / Committees and induction of new Independent directors in process.**

## ESG principles deeply rooted in PI's culture and way of doing business

- CII-National Award for 'Excellence in Water Management 2020'
- 99 out of 100 score on TfS assessment won customer award
- Established process for identifying climate risks both, physical & transition
- Accredited environmental management systems & infrastructure
- Sustainability Council with effective framework focusing on ESG goals
- Board & committee composition, Separate roles for NEC and MD, performance linked remuneration structures, etc ensuring high governance standards.
- Revenue growth in FY21 by 30% YoY
- No Penalties imposed for material noncompliance w.r.t Corporate governance
- Robust information & cyber security infrastructure / ISO 27001 certification
- Disclosure of material issues in public reporting.
- Assured per AA1000 Assurance Standard on ESG indicators





- Gold Star Rating: Ecovardis Survey
- Hazardous waste reduction by 35% YoY
- Increase in Renewable energy consumption by 6X YoY
- Water consumption (specific) reduced by 17% YoY

- Winner at World Leadership Congress CSR Programme of Year for Direct Seeding Rice Initiative
- Won Global Excellence HR Award 2020
- Committed to Responsible Care<sup>®</sup> & Human Rights
- 99% workforce training on Code of Conduct
- NIL fatality cases reported in 2020-21
- Employment rate increased by 24% YoY
- Extensive efforts on product stewardship
- Significant spend on social projects impacting women empowerment, skill dev., health and sustainable agriculture.
- Share of women in STEM positions @ 10%

## **Pl's value proposition**



|   | 2   | 3   | 4  | 5   | 6   |
|---|---|---|--|---|---|
| Favorable dynamics<br>driving Indian chemical<br>industry growth  | Business model ready<br>to go beyond Ag-Chem  | Offerings across the value chain driven by strategic partnership  | Strong tangibles: R&D,<br>manufacturing,<br>extensive network of<br>intangibles: Brands  | Quality governance,<br>talent & learning skills   | Performance over a<br>long term period  |
| <ul> <li>Global specialty chemicals<br/>market expected to grow at<br/>6.4% CAGR<sup>1</sup></li> <li>Increasing focus on CSM as<br/>innovators shift focus to core<br/>competencies, developing<br/>new active ingredients and<br/>outsource production</li> <li>M&amp;A activities boosting<br/>specialized CSM players</li> <li>Emerging new areas of<br/>innovative applications</li> <li>Global supply chain risk<br/>diversification: China facing<br/>issues – pollution, trade<br/>wars, safety issues</li> </ul> | <ul> <li>Business built on end-to-<br/>end partnerships with global<br/>innovators</li> <li>~90% CSM revenues from<br/>patented molecules; 70%+<br/>domestic revenues from in-<br/>licensed molecules</li> <li>Proven capabilities in<br/>agrochemicals; now ready to<br/>be replicated across other<br/>fine chemicals segments</li> <li>Envisaging expeditious<br/>scaleup of <b>pharma vertical</b> via<br/>strategic acquisition of API &amp;<br/>intermediates business</li> </ul> | <ul> <li>Integrated and innovative services to provide</li> <li>Comprehensive solutions by partnerships</li> <li>Relationships with 20+ global innovators built on IP protection</li> </ul> | <ul> <li>Globally certified with use of<br/>Technology, 4 manufacturing<br/>facilities, 16 production<br/>blocks</li> <li>6 formulation facilities</li> <li>R&amp;D team of ~350 researchers<br/>and scientists</li> <li>Digital technology enabled<br/>in domestic process in<br/>business processes</li> </ul> | <ul> <li>Professionals with expertise across various technical and business functions</li> <li>Senior management team of qualified experienced professionals</li> </ul> | <ul> <li>Revenue CAGR (FY18-<br/>FY21) of 25.6%<sup>2</sup></li> <li>EBITDA CAGR (FY18-FY21) of 27.2%<sup>3</sup></li> <li>Pre-tax RoCE of more than 20% over last 4 years<sup>4</sup></li> </ul> |

#### Well-positioned to capture value from changing market landscape

Note: (1) FY19-24 CAGR;Source: Frost & Sullivan; (2) Revenue = Revenue from operating - excise duty; (3) EBITDA = Revenue - Cost of Materials consumed - Purchase of Stock in Trade - Changes in Inventories of FG, WIP and stock in trade - Employee Benefits expense - Other Expenses; (4) Pre-tax RoCE%= (EBITDA – D&A) / Average Capital Employed (CE); CE=Net Debt + Total Equity.

## Track record of building several successful businesses, partnerships and industry leading brands



|   |                              |  |                      |   |                              | 「0 "つ<br>「2~2  |  |
|---|------------------------------|--|----------------------|---|------------------------------|--|--|
| Inception   |                              | New Business   |                      | New Geography   |                              | New Partnership  |  |
| Founded as The<br>Mewar Oil and<br>General Mills Ltd. | 1961<br>1971<br>1976<br>1985 | Ag-Chem Formulation and Marketing<br>Mining later hived off<br>First Technical Manufacturing plant<br>Energy Metering, later hived off | 2004<br>2007<br>2008 | PI Life Science Research Ltd.<br>Established Subsidiary in Japan<br>(PI Japan Co. Ltd)<br>Started New Rep Office in<br>China (Shanghai) | 2011<br>2011<br>2014<br>2015 | <ul> <li>GLP Certification</li> <li>Inauguration of PI-Sony Research Centre</li> <li>Germany office</li> <li>Formulation site setup at Panoli<br/>(Gujarat)</li> </ul> |  |
|   | 1992<br>1993                 | Name Changed to PI Industries Limited<br>Facility at Panoli (Gujarat)  |                      |   | 2016                         | Joint Venture – Solinnos<br>New R&D Centre at Udaipur  |  |

1993 PILL Finance and Investment Ltd.

implement SAP

1946

- 1995 Polymer Compounding later divested
- 1996 Custom Synthesis & Manufacturing 1st company in the Ag-chem to 2001
  - **Continuingly creating value propositions for the stakeholders**

M&A – acquired Isagro Asia

QIP fund-raise Rs. 2000cr

2017

2019

2020

Joint Venture – PI Kumiai Pvt. Ltd.

## Business model built on the principles of respect for IP and established relationships




| D   | omestic Brand Market   | Leading Ag-chem Distribution<br>Company in India with<br>leading market share in<br>certain crops   | India's largest CRAMS<br>with over 90% Revenu<br>Patented Products  |                      | Exports Market  | Inspired by Science |
|---|--|---|---|----------------------|---|---------------------|
| demonstra<br>experier                     | raging our Pan India network,<br>ting brand building capabilities a<br>nced team to deliver in-licensed,<br>generics & co-marketed product   | R   | &D<br>ership  | and manufa           | on chemistry process resea<br>acturing capabilities caterin<br>ators; Partnering for IP Cre                                   | ng to               |
| global inn<br>• Ensure lor<br>• Develop s | ng new products, partnering with   | g Common In<br>Develop k<br>products, processe<br>different comp  | C APPROACH<br>ofrastructure<br>nowledge,<br>es and experience in<br>olex chemistries<br>Opportunities   | • Ea<br>• Cc<br>• Pr | stom Synthesis & M<br>arly stages of their life cycles<br>omplex Chemistries<br>rocess development<br>Protection & Generation | •                   |
|   | <ul> <li>State of the Art R&amp;D facilities         <ul> <li>~350 researchers and<br/>scientists</li> <li>Accredited for GLP and 'Norms<br/>on OECD Principles' by NGCMA</li> </ul> </li> </ul> | <ul> <li>To service its customers</li> <li>1 R&amp;D Facility</li> <li>4 Manufacturing Sites</li> <li>Domestic Brand Distribution <ul> <li>28 stock points</li> <li>10,000+ distributors</li> <li>70,000 retail points</li> </ul> </li> </ul> | <ul> <li>3 Global locations</li> <li>Japan for business<br/>development activities</li> <li>China for Sourcing</li> <li>Germany for Knowledge<br/>Management</li> </ul> |                      | nsistent track record of<br>ancial performance  |                     |

Non conflicting business model ... well respected by Global Innovators as Partners

## Presence across the agchem value chain

Strong focus on customer needs and continuous innovation




**Inspired by Science** 

## **Differentiated domestic distribution model**

#### Driven by unique solutions thru global partnerships, brands building capabilities and market reach







### Custom Synthesis & Manufacturing (CSM) model is centered around our technological capabilities, high sustainability quotient and world class infrastructure



To be the lifelong Partner of Choice for the Global Chemicals Industry by building innovative, knowledge-based solutions through speed, efficiency, straightforwardness & just dealings, respect for intellectual property, society & environment



## Global tailwinds offering opportunities for aggressive and multi-pronged growth strategy



Prudent financial management in place to ensure that long term shareholder value creation remains at the heart of the strategy

## Domestic agri input market is expected to grow fast and PI is well positioned to capitalize this opportunity



8-10% projected CAGR between 2020 to 2025

Ingredients in place for PI to capitalize this opportunity

Strong novel offerings with focus on in-licensing

3 / 4 exclusive launches

- 25+ products in the pipeline
- Supported by new product launches

Dedicated verticals for horticulture crops through Jivagro

 >25% CAGR growth estimated over next 4-5 years


- Extensive Distribution Network
- Robust brand building capabilities
- Leadership position in key crops



# With Indian gaining good market share of the global Specialty Chemical market, PI is consolidating its position with diversification into adjacencies

protection


Global Specialty Chemicals Industry size (USD bn) 1,171



expertise

advancements

Indian Specialty Chemicals Industry size (USD bn)



#### Factors that will elevate growth for Indian Companies

| India's<br>emergence as<br>an export hub<br>for global<br>innovators | Increase in<br>outsourcing<br>manufacturing<br>activities to<br>India | Leadership<br>position in<br>select niche<br>molecules and<br>chemistries | Benefits<br>accruing out<br>of supply<br>chain<br>diversification | Focus on<br>green<br>chemistry<br>through<br>adoption of<br>sustainable<br>manufacturing<br>practices |
|--|---|---|---|---|

*Source:* FICCI Report on Indian Specialty Chemicals Industry

molecules

### **Proactive initiatives contained Covid-19 disruption** SOPs in place with regular reviews / vigilant oversight to ensure safety of employees and continuity of operations



SOPs have been instituted to focus on alleviation of suffering of the citizenry, reassurance of customer base and maintenance of business momentum

**Stringent protocols for streamlining operating and non-operating processes are in place**. Workplace hygiene and safety steps have been taken to underline minimal disruption to routine functionality

**Customer commitment is a hallmark of our business approach**. Through pro-active communication clients are being reassured and their needs are getting assessed, in real-time basis. Deployment of digital methods last year helped achieve **connect with farmers** and key constituents of the distribution chain, these are being activated again

Manufacturing facility level processes have been augmented. **Inventories of critical feedstock and ingredients are being optimally maintained such that the chain of dispatches remains un-broken.** Measures to attend to the needs of the associated workforce are also in place

Government-based organizations and NGOs are being supported to mitigate hardships and facilitate care, where it is most required. Various employee welfare initiatives such as **providing insurances**, **vaccination drives**, **safe employee bio-bubble**, **oxygen concentrators/cylinders**, **salary advances**, etc. are also undertaken









## Doing our bit to support govt effort and communities around us to fight Covid-19



| Setting-up of 5<br>Oxygen Generation<br>Plants  | Provision for<br>Oxygen<br>Concentrators  | Financial assistance<br>in setting up Covid<br>Isolation Centres   | Assistance to<br>procure CT Scan<br>machine   | Support of<br>Medicines for<br>Underprivileged  | Awareness<br>Campaigns  | PI Volunteers for<br>community support  |
|---|---|--|---|---|---|---|
| <ul> <li>Amidst the deadly<br/>second wave<br/>coupled with<br/>shortage of medical<br/>oxygen, PI Industries<br/>quickly rolled out for<br/>setting up of 5<br/>oxygen generation<br/>plants across 5<br/>hospitals in Gujarat,<br/>Rajasthan and Delhi</li> </ul> | <ul> <li>Financial<br/>assistance to the<br/>Udaipur<br/>Chamber of<br/>Commerce and<br/>Industry (UCCI)<br/>for procuring<br/>oxygen<br/>concentrator<br/>machines during<br/>this crisis</li> </ul> | <ul> <li>Provided 50 beds<br/>and requisite<br/>medical equipment<br/>to Covid-19<br/>Isolation Centre at<br/>Jambusar &amp;<br/>assistance to Vasant<br/>Vihar Welfare<br/>Association, New<br/>Delhi for running<br/>Covid Isolation<br/>Centre</li> </ul> | <ul> <li>Financial<br/>assistance to<br/>Arogya dham<br/>Hospital, Gwalior<br/>to procure CT<br/>Scan machine to<br/>facilitate better<br/>diagnostics &amp;<br/>treatment for<br/>Covid 19 patients</li> </ul> | <ul> <li>Financial<br/>assistance to<br/>Rotary welfare<br/>Trust, Bharuch<br/>for procuring<br/>expensive<br/>lifesaving<br/>medicines to<br/>support the<br/>underprivileged<br/>community</li> </ul> | <ul> <li>3 Mobile Med.<br/>Vans</li> <li>Community<br/>outreach programs<br/>covered &gt;46,000<br/>people in 64<br/>villages</li> <li>~300 people are<br/>screened daily</li> <li>Free Health Camps<br/>on Gynecology &amp;<br/>RCH</li> </ul> | <ul> <li>PI employees are<br/>volunteering to support<br/>the community (family<br/>and friends of<br/>employees) by forming<br/>self-help groups that<br/>are working round the<br/>clock to provide<br/>assistance in sharing<br/>updated and verified<br/>information</li> </ul> |



# Our CSR efforts have focused on Community welfare & Environment



#### PI's CSR strategy focuses on:

- Creating a positive impact for marginalized communities via environmentally sustainable approach
- Interventions align with several Sustainable Development Goals (SDG)
- Continuous life cycle evaluation of products and product stewardship to minimize ecoimpact

#### Implementation

| Sustainable Agriculture<br>Practice                 | <b>700K+</b> Hectares of Farmlands benefitted by DSR technique thereby saving <b>1.7 trillion</b> litres of Water annually    |
|---|---|
| Healthcare, Hygiene and<br>Sanitation Interventions | <b>100K+</b> Lives impacted using Mobile Healthcare Vans under <b>PI's 'Swasthya Seva"</b> Initiative and Blood Bank services |
| Women Empowerment                                   | <b>15K+</b> Women across <b>82</b> villages in Bharuch Area benefitted through PI's women empowerment program                 |
| Education Interventions                             | <b>18K+</b> Govt. school children across <b>125 Schools</b> benefitted through PI's Learning Enhancement Programmes           |
| Skill Development                                   | <b>2.0K+</b> Youth employed through large scale Skill Development Programmes  |

#### **Key Programmes and Initiatives**

- Water conservation through sustainable agriculture practices & farm engagement activities
- SWASTHYA Seva Initiative Aim to provide access to preventive, promotive & curative health care to underprivileged
- Learning enhancement programmes for government school children in 135 schools
- Certified vocational training & employability linked skill enhancement program for underprivileged youth
- Entrepreneurship development & livelihood promotion through sustained agriculture, dairy value chain & skill training for rural women
- Community Drinking Water
   Initiative and construction of
   school toilets







PI Industries Ltd. Corporate Off: 5th Floor, Vipul Square, B Block, Sushant Lok, Phase - 1, Gurgaon - 122009 (Har), India; Tel: +91 124 6790000, Fax: +91 124 4081247. Regd. Off: Udaisagar Road, Udaipur - 313001; Tel: +91 294 2491451-5, Fax: +91 294 2491946. www.piindustries.com